Please login to the form below

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene raises $903m from Hong Kong IPO

China’ s BeiGene raises $903m from Hong Kong IPO. Mammoth debut might have exceeded $1bn but for market jitters. ... BeiGene’s shares are expected to begin trading on the HKEX on 8 August under the stock code “06160”.

Latest news

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

Read the NHS' internal briefing on adalimumab biosimilars from May. Hong Kong could be new biotech hub, says Beigene, heading for $1bn floatation. ... Beigene is part of a wave of new China-based biotech companies who are emerging rapidly thanks to new
Keytruda is first I-O drug cleared for melanoma in China

China’s pharma industry isn’t resting on its laurels, however, and Beijing company BeiGene said earlier this week it plans to file for approval of its PD-1 inhibitor tislelizumab
China’s BeiGene takes PD-1 antibody into pivotal trials

market. Now, BeiGene is aiming to leapfrog the leaders with its tislelizumab candidate. ... Not all of BeiGene’s programmes are directed solely to the Chinese market.
Celgene joins PD-1 race via partnership with BeiGene

Celgene joins PD-1 race via partnership with BeiGene. The pharma giant will pay the Chinese firm up to $980m in milestone payments. ... Celgene's push into immuno-oncology has continued with a $1.4bn agreement to license ex-Asian rights to BeiGene's PD-1
Merck KGaA to research cancer drug with Chinese biotech

Merck KGaA has entered a collaboration with China-based biotech BeiGene to research a new treatment for cancer. ... The agreement sees Merck pay BeiGene an undisclosed upfront fee as well as several clinical and commercial milestones.

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
Made in China

The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
Deal Watch March 2017

In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
Deal Watch table for November 2013

BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer: Competitive Salary

Associate Editorial Director – Med Comms – London: Salary TBC

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Associate Director: £75, 000-90, 000

Account Director: Excellent benefits

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Associate Medical Director: Highly Competitive

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Medical/ Scientific Director: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager: Negotiable

Associate Director, Market Access & HEOR – North-West: Negotiable

Medical Writers: Competitive Salary and Benefits

Consultant Health Economics - London / Oxford: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Events Manager – Med Comms – Surrey: Salary TBC

New Business Director - PR: Competitive Salary and benefits

Account Director: £48, 000 - £60, 000

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Subscribe to our email news alerts

PMHub

Add my company

90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...